Trial
NCT01939223
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
—
Condition
Colorectal Neoplasms
Intervention
Regorafenib (Stivarga, BAY73-4506)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-20